Expertise in
1
conditions

Dr. Ann Childress

Child and Adolescent Psychiatry
Office
7351 Prairie Falcon Rd Ste 160, 
Las Vegas, NV 
Expertise in
1
conditions
Office
7351 Prairie Falcon Rd Ste 160, 
Las Vegas, NV 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ann Childress is a Child and Adolescent Psychiatrist in Las Vegas, Nevada. Dr. Childress is highly rated in 1 condition, according to our data. Her top areas of expertise are Attention Deficit Hyperactivity Disorder (ADHD) and Stereotypic Movement Disorder.

Her clinical research consists of co-authoring 125 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Child and Adolescent Psychiatry
Licenses
Child & Adolescent Psychiatry in NV
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
SelectHealth
  • HMO
  • POS
Silversummit Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

Office
7351 Prairie Falcon Rd Ste 160, Las Vegas, NV 89128
Other Locations
Richard David Washinsky MD LTD
2851 N Tenaya Way, Las Vegas,, NV 89128

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: September 08, 2025
Intervention Type: Drug, Other
Study Drugs: Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride
Study Phase: Phase 4
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drug: SPN-812
Study Phase: Phase 3
Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant (STARS-ADHD Adjunctive)
Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant (STARS-ADHD Adjunctive)
Enrollment Status: Completed
Publish Date: August 09, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD)
A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Phase: Phase 4
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: June 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: March 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: August 14, 2020
Intervention Type: Device
Study Phase: Not Applicable
Pharmacokinetic Pharmacodynamic Studies of Methylphenidate Extended Release Products in Pediatric Attention Deficit Hyperactivity Disorder
Pharmacokinetic Pharmacodynamic Studies of Methylphenidate Extended Release Products in Pediatric Attention Deficit Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: December 10, 2019
Intervention Type: Drug
Study Phase: Not Applicable
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Children (6-12 Years of Age) With ADHD
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Children (6-12 Years of Age) With ADHD
Enrollment Status: Completed
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 3
An Exploratory Study to Assess the Sustained Effects of Digital Therapy in Pediatric Subjects 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
An Exploratory Study to Assess the Sustained Effects of Digital Therapy in Pediatric Subjects 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: February 12, 2019
Intervention Type: Device
Study Phase: Not Applicable
A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)
A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: April 06, 2017
Intervention Type: Drug
Study Phase: Phase 2
Reference Database Development for the Quotient® System iPad Test (Ages 6 - 80 Years Old)
Reference Database Development for the Quotient® System iPad Test (Ages 6 - 80 Years Old)
Enrollment Status: Completed
Publish Date: April 05, 2017
Intervention Type: Device
Study Phase: Not Applicable
View 12 Less Clinical Trials

125 Total Publications

A Matching-Adjusted Indirect Comparison (MAIC) of Centanafadine versus Methylphenidate Hydrochloride in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): Short-Term Safety and Efficacy Outcomes: Comparaison indirecte ajustée par appariement (MAIC) entre centanafadine et le chlorhydrate de méthylphénidate chez les adultes atteints d'un trouble déficitaire de l'attention avec ou sans hyperactivité (TDAH) : Résultats en matière d'innocuité et d'efficacité à court terme.
A Matching-Adjusted Indirect Comparison (MAIC) of Centanafadine versus Methylphenidate Hydrochloride in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): Short-Term Safety and Efficacy Outcomes: Comparaison indirecte ajustée par appariement (MAIC) entre centanafadine et le chlorhydrate de méthylphénidate chez les adultes atteints d'un trouble déficitaire de l'attention avec ou sans hyperactivité (TDAH) : Résultats en matière d'innocuité et d'efficacité à court terme.
Journal: Canadian journal of psychiatry. Revue canadienne de psychiatrie
Published: June 02, 2025
Similar Doctors
Expertise in
11
conditions
Dr. Sapandeep Khurana
Child and Adolescent Psychiatry
Expertise in
11
conditions
Dr. Sapandeep Khurana
Child and Adolescent Psychiatry

Nevada Mental Health

6600 W Charleston Blvd Ste 142, 
Las Vegas, NV 
 (7.8 miles away)
702-440-8430
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sapandeep Khurana is a Child and Adolescent Psychiatrist in Las Vegas, Nevada. Dr. Khurana is highly rated in 11 conditions, according to our data. His top areas of expertise are Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder (GAD), Major Depression, and Attention Deficit Hyperactivity Disorder (ADHD).

Expertise in
12
conditions
Dr. Colin Freedman
Child and Adolescent Psychiatry
Expertise in
12
conditions
Dr. Colin Freedman
Child and Adolescent Psychiatry

Focus Mental Health Solutions

660 S Green Valley Pkwy Ste 140, 
Henderson, NV 
 (14.2 miles away)
Languages Spoken:
English
See accepted insurances

Colin Freedman is a Child and Adolescent Psychiatrist in Henderson, Nevada. Dr. Freedman is highly rated in 12 conditions, according to our data. His top areas of expertise are Generalized Anxiety Disorder (GAD), Major Depression, Seasonal Affective Disorder (SAD), and Post-Traumatic Stress Disorder (PTSD).

Expertise in
7
conditions
Dr. Emmanuel Nwapa
Child and Adolescent Psychiatry
Expertise in
7
conditions
Dr. Emmanuel Nwapa
Child and Adolescent Psychiatry

Office

3131 W Charleston Blvd Ste 150, 
Las Vegas, NV 
 (5.4 miles away)
702-854-5000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Emmanuel Nwapa is a Child and Adolescent Psychiatrist in Las Vegas, Nevada. Dr. Nwapa is highly rated in 7 conditions, according to our data. His top areas of expertise are Bipolar Disorder (BPD), Major Depression, Schizophrenia, and Seasonal Affective Disorder (SAD).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Childress's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile